Sex steroids are major promoters of the growth of breast and prostate cancers. This Review by Poutanen et al. describes the development of treatments for these cancer types that act to restrict sex steroid availability for receptor binding by inhibiting steroid biosynthesis, being a complementary mechanism of action to the more traditional sex steroid antagonists.
- Matti Poutanen
- Malin Hagberg Thulin
- Pirkko Härkönen